226 related articles for article (PubMed ID: 30273516)
1. Glutaminase inhibitors: a patent review.
Wu C; Chen L; Jin S; Li H
Expert Opin Ther Pat; 2018 Nov; 28(11):823-835. PubMed ID: 30273516
[TBL] [Abstract][Full Text] [Related]
2. Recent Development of Small Molecule Glutaminase Inhibitors.
Song M; Kim SH; Im CY; Hwang HJ
Curr Top Med Chem; 2018; 18(6):432-443. PubMed ID: 29793408
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer.
Matés JM; Di Paola FJ; Campos-Sandoval JA; Mazurek S; Márquez J
Semin Cell Dev Biol; 2020 Feb; 98():34-43. PubMed ID: 31100352
[TBL] [Abstract][Full Text] [Related]
4. A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis.
Katt WP; Lukey MJ; Cerione RA
Future Med Chem; 2017 Jan; 9(2):223-243. PubMed ID: 28111979
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition.
Ulanet DB; Couto K; Jha A; Choe S; Wang A; Woo HK; Steadman M; DeLaBarre B; Gross S; Driggers E; Dorsch M; Hurov JB
PLoS One; 2014; 9(12):e115144. PubMed ID: 25502225
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Evaluation of Thiazolidine-2,4-dione Derivatives as a Novel Class of Glutaminase Inhibitors.
Yeh TK; Kuo CC; Lee YZ; Ke YY; Chu KF; Hsu HY; Chang HY; Liu YW; Song JS; Yang CW; Lin LM; Sun M; Wu SH; Kuo PC; Shih C; Chen CT; Tsou LK; Lee SJ
J Med Chem; 2017 Jul; 60(13):5599-5612. PubMed ID: 28609101
[TBL] [Abstract][Full Text] [Related]
7. Mcl-1 inhibitors: a patent review.
Chen L; Fletcher S
Expert Opin Ther Pat; 2017 Feb; 27(2):163-178. PubMed ID: 27744724
[TBL] [Abstract][Full Text] [Related]
8. Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
Xu X; Meng Y; Li L; Xu P; Wang J; Li Z; Bian J
J Med Chem; 2019 Feb; 62(3):1096-1115. PubMed ID: 30148361
[TBL] [Abstract][Full Text] [Related]
9. Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase.
Zimmermann SC; Duvall B; Tsukamoto T
J Med Chem; 2019 Jan; 62(1):46-59. PubMed ID: 29969024
[TBL] [Abstract][Full Text] [Related]
10. Glutaminase isoenzymes in the metabolic therapy of cancer.
Matés JM; Campos-Sandoval JA; Márquez J
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):158-164. PubMed ID: 30053497
[TBL] [Abstract][Full Text] [Related]
11. Q-ing tumor glutaminase for therapy.
Stine ZE; Dang CV
Oncotarget; 2015 Nov; 6(36):38440-1. PubMed ID: 26564960
[No Abstract] [Full Text] [Related]
12. Multifunctional antitumor molecule 5'-triphosphate siRNA combining glutaminase silencing and RIG-I activation.
Meng G; Xia M; Xu C; Yuan D; Schnurr M; Wei J
Int J Cancer; 2014 Apr; 134(8):1958-71. PubMed ID: 23921958
[TBL] [Abstract][Full Text] [Related]
13. A patent review of FGFR4 selective inhibition in cancer (2007-2018).
Quintanal-Villalonga A; Ferrer I; Molina-Pinelo S; Paz-Ares L
Expert Opin Ther Pat; 2019 Jun; 29(6):429-438. PubMed ID: 31146605
[TBL] [Abstract][Full Text] [Related]
14. Physapubescin, a natural withanolide as a kidney-type glutaminase (KGA) inhibitor.
Cheng L; Wu CR; Zhu LH; Li H; Chen LX
Bioorg Med Chem Lett; 2017 Mar; 27(5):1243-1246. PubMed ID: 28174105
[TBL] [Abstract][Full Text] [Related]
15. Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors.
Thomas AG; Rojas C; Tanega C; Shen M; Simeonov A; Boxer MB; Auld DS; Ferraris DV; Tsukamoto T; Slusher BS
Biochem Biophys Res Commun; 2013 Aug; 438(2):243-8. PubMed ID: 23850693
[TBL] [Abstract][Full Text] [Related]
16. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
Lampa M; Arlt H; He T; Ospina B; Reeves J; Zhang B; Murtie J; Deng G; Barberis C; Hoffmann D; Cheng H; Pollard J; Winter C; Richon V; Garcia-Escheverria C; Adrian F; Wiederschain D; Srinivasan L
PLoS One; 2017; 12(9):e0185092. PubMed ID: 28950000
[TBL] [Abstract][Full Text] [Related]
17. The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.
Bertero T; Perk D; Chan SY
Expert Opin Ther Targets; 2019 Jun; 23(6):511-524. PubMed ID: 31055988
[TBL] [Abstract][Full Text] [Related]
18. Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity.
Chen Z; Li D; Xu N; Fang J; Yu Y; Hou W; Ruan H; Zhu P; Ma R; Lu S; Cao D; Wu R; Ni M; Zhang W; Su W; Ruan BH
J Med Chem; 2019 Jan; 62(2):589-603. PubMed ID: 30543285
[TBL] [Abstract][Full Text] [Related]
19. [
Zhou R; Pantel AR; Li S; Lieberman BP; Ploessl K; Choi H; Blankemeyer E; Lee H; Kung HF; Mach RH; Mankoff DA
Cancer Res; 2017 Mar; 77(6):1476-1484. PubMed ID: 28202527
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
